Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Neuropsychiatr Dis Treat · 2007 · PMC2656320 · PMID 19300613

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

possibly not significantno p-value reported

A pharmacoeconomic assessment performed by Willan et al (2006) was possibly not significant because of the variability of drug costs and the short, six-month study period.

also in 22 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.